Abstract
Rui-Hua Xu completed the REGOTORI trial that showed a novel combination regimen, regorafenib plus toripalimab, improved the efficacy and survival of r......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
